Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 5/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.45 |
| ▸ | GLP1R | P43220 | 12/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30021781 | 1.00 | PTGER1 (0.46) | PTGER1CYP2C9CYP2C19CYP1A2TBXA2R | |
| SCHEMBL25198298 | 0.92 | PTGER1 (0.46) | PTGER1CYP2C9CYP2C19CYP1A2TBXA2R | |
| SCHEMBL29608428 | 0.91 | PTGER1 (0.46) | PTGER1CYP2C9CYP2C19CYP1A2TBXA2R | |
| SCHEMBL24900032 | 0.91 | PTGER1 (0.46) | PTGER1CYP2C9CYP2C19CYP1A2TBXA2R | |
| SCHEMBL25203119 | 0.89 | PTGER1 (0.44) | PTGER1CYP2C9CYP2C19CYP1A2TBXA2R | |
| SCHEMBL30020671 | 0.89 | PTGER1 (0.49) | PTGER1CYP2C9CYP2C19CYP1A2TBXA2R | |
| SCHEMBL23481374 | 0.89 | PTGER1 (0.49) | PTGER1CYP2C9CYP2C19CYP1A2TBXA2R | |
| SCHEMBL25734582 | 0.88 | PTGER1 (0.44) | PTGER1CYP2C9CYP2C19CYP1A2TBXA2R | |
| SCHEMBL28935413 | 0.87 | PTGER1 (0.42) | PTGER1CYP2C9CYP2C19CYP1A2TBXA2R | |
| SCHEMBL24900227 | 0.87 | PTGER1 (0.48) | PTGER1CYP2C9CYP2C19CYP1A2TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115279750-B | GLP-1 receptor agonist, pharmaceutical composition containing same and preparation method thereof | 株式会社LG化学 | 2024-06-21 | — | — | CN | disclosed |
| US-20230203021-A1 | GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND METHOD FOR PREPARING SAME | LG CHEM, LTD. (KR) | 2023-06-29 | — | — | US | disclosed |
| US-20230165846-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230165846-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-01 | — | — | US | disclosed |
| CN-115697999-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-4119555-A1 | GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND METHOD FOR PREPARING SAME | Lg Chem, Ltd. (KR) | 2023-01-18 | — | — | EP | disclosed |
| CN-115279750-A | GLP-1 receptor agonist, pharmaceutical composition containing same and preparation method thereof | 株式会社LG化学 | 2022-11-01 | — | — | CN | disclosed |
| WO-2021160127-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165846-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | PTGER1 131/4885CYP2C9 996/4885CYP2C19 533/4885 |
| US-20230203021-A1 | GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND METHOD FOR PREPARING SAME | GLP1R, GIPR, GPR119 | PTGER1 772/4885CYP2C9 2815/4885CYP2C19 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.